Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1429343

Evaluating the feasibility and predictive accuracy of Biodynamic Imaging to Platinum-Based Chemotherapy Response in Esophageal Adenocarcinoma

Provisionally accepted
Ali Ajrouch Ali Ajrouch 1*Ben Krempley Ben Krempley 1Ahmad Karkash Ahmad Karkash 1John M. Dewitt John M. Dewitt 2Mohammad Al-Haddad Mohammad Al-Haddad 2Dawith Lim Dawith Lim 3David Nolte David Nolte 3John Turek John Turek 3Susan Perkins Susan Perkins 2Shadia I. Jalal Shadia I. Jalal 1
  • 1 Melvin and Bren Simon Comprehensive Cancer Center, Department of Medicine, School of Medicine, Indiana University Bloomington, Indianapolis, United States
  • 2 School of Medicine, Indiana University Bloomington, Indianapolis, Indiana, United States
  • 3 Purdue University, West Lafayette, Indiana, United States

The final, formatted version of the article will be published soon.

    Background: Esophageal cancer management lacks reliable response predictors to chemotherapy. In this study we evaluated the feasibility and accuracy of Biodynamic Imaging (BDI), a technology that employs digital holography as a rapid predictor of chemotherapy sensitivity in locoregional esophageal adenocarcinoma.Methods: Pre-treatment endoscopic pinch biopsies were collected from patients with esophageal adenocarcinoma during standard staging procedures. BDI analyzed the tumor samples and assessed in vitro chemotherapy sensitivity. BDI sensitivity predictions were compared to patients' pathological responses, the gold standard for determining clinical response, in the surgically treated subset (n=18).Result: BDI was feasible with timely tissue acquisition, collection, and processing in all 30 enrolled patients and successful BDI analysis in 28/29 (96%) eligible. BDI accurately predicted chemotherapy response in 13/18 (72.2%) patients using a classifier for complete, marked, and partial/no-response. BDI technology had 100% negative predictive value for complete pathological response hence identifying patients unlikely to respond to treatment.: BDI technology can potentially predict patients' response to platinum chemotherapy. Additionally, this technology represents a promising step towards optimizing treatment strategies for esophageal adenocarcinoma patients by pre-emptively identifying nonresponders to conventional platinum-based chemotherapy.

    Keywords: Esophageal adenocarcinoma, biodynamic imaging, chemotherapy response prediction, Patient-Specific Modeling, Digital Holography, precision oncology, Platin Agents

    Received: 08 May 2024; Accepted: 30 Aug 2024.

    Copyright: © 2024 Ajrouch, Krempley, Karkash, Dewitt, Al-Haddad, Lim, Nolte, Turek, Perkins and Jalal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ali Ajrouch, Melvin and Bren Simon Comprehensive Cancer Center, Department of Medicine, School of Medicine, Indiana University Bloomington, Indianapolis, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.